Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma

Background Patients with V600BRAF mutant metastatic melanoma have higher rates of progression-free survival (PFS) and overall survival (OS) with first-line anti-PD1 (PD1]+anti-CTLA-4 (IPI) versus PD1. Whether this is also true after BRAF/MEKi therapy is unknown. We aimed to determine the efficacy an...

Full description

Bibliographic Details
Main Authors: Lisa Zimmer, Serigne Lo, Celeste Lebbe, Olivier Michielin, Ines Pires da Silva, Paolo Antonio Ascierto, Matteo Carlino, Alexander Menzies, Douglas B Johnson, Claudia Trojanello, Georgina Long, Tasnia Ahmed, Clara Allayous, Johanna Mangana, Florentia Dimitriou, Danny Zakria, Camille Gerard
Format: Article
Language:English
Published: BMJ Publishing Group 2022-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/7/e004610.full

Internet

https://jitc.bmj.com/content/10/7/e004610.full

Similar Items